As an Infectious Diseases Physician Scientist, my research has been focused on improving the lives of HIV-infected individuals by imporving long-term outcomes of infection and treatment. This work includes collaborations with the AIDS Clinical Trials Group (ACTG), the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) group, and teams of multi-disciplinary investigators, and has bridged outcomes-epidemiology research, translational research, and clinical trials. This work has led to successful NIH-funded grants on which I have served as principal investigator or co-investigator. I have a strong track record of successfully leading and contributing to collaborative clinical-translational research in inflammation, oxidative stress, and genomics that has produced peer-reviewed publications of high relevance.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality. Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, Hulgan T, Bryant KJ, Zhao H, Krystal JH, Justice AC, Xu K (2018) Clin Epigenetics 10(1): 155
    › Primary publication · 30545403 (PubMed) · PMC6293604 (PubMed Central)
  2. Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. Hulgan T, Kallianpur AR, Guo Y, Barnholtz-Sloan JS, Gittleman H, Brown TT, Ellis R, Letendre S, Heaton RK, Samuels DC, CHARTER Study (2019) J Acquir Immune Defic Syndr 80(4): e95-e102
    › Primary publication · 30531306 (PubMed) · PMC6391216 (PubMed Central)
  3. Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT (2019) J Acquir Immune Defic Syndr 80(3): 358-366
    › Primary publication · 30531304 (PubMed) · PMC6375746 (PubMed Central)
  4. Precision HIV care: responding to old questions and meeting new challenges. Hulgan T, Dash C, Haas DW, Phillips EJ (2018) Pharmacogenomics 19(17): 1299-1302
    › Primary publication · 30325267 (PubMed)
  5. Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Kallianpur AR, Gittleman H, Letendre S, Ellis R, Barnholtz-Sloan JS, Bush WS, Heaton R, Samuels DC, Franklin DR, Rosario-Cookson D, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, McCutchan JA, Morgello S, Grant I, Simpson D, Connor JR, Hulgan T, CHARTER Study Group (2019) Mol Neurobiol 56(5): 3808-3818
    › Primary publication · 30209774 (PubMed) · PMC6952215 (PubMed Central)
  6. Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment. Smieszek S, Jia P, Samuels DC, Zhao Z, Barnholtz-Sloan J, Kaur H, Letendre S, Ellis R, Franklin DR, Hulgan T, Kallianpur A, Bush WS, CHARTER Study Group (2019) Mitochondrion : 247-255
    › Primary publication · 30026132 (PubMed) · PMC6336535 (PubMed Central)
  7. Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Marquine MJ, Heaton A, Johnson N, Rivera-Mindt M, Cherner M, Bloss C, Hulgan T, Umlauf A, Moore DJ, Fazeli P, Morgello S, Franklin D, Letendre S, Ellis R, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Simpson D, McCutchan JA, Grant I, Heaton RK (2018) J Int Neuropsychol Soc 24(2): 163-175
    › Primary publication · 28874213 (PubMed) · PMC5777885 (PubMed Central)